ALSO NOTED: Osteologix reports positive Phase II; Crestor fails in heart study; Wyeth CEO: FDA creating monopoly meds; and much

> Osteologix says it harvested positive top-line results in an international Phase II clinical trial of its lead investigational drug, NB S101 (strontium malonate). The trial of 289 postmenopausal women with low bone mineral density met its primary endpoint by significantly decreasing CTX-1, a biomarker for measuring bone resorption activity, at all dose levels compared with the control group. Release

> AstraZeneca's Crestor failed to reduce deaths from heart failure among older people suffering from heart failure. AstraZeneca had been looking to expand the market for its blockbuster cholesterol drug. Report

> Transition Therapeutics has regained all rights to E1-I.N.T after it failed to reach an exclusive licensing pact with Novo Nordisk. Transition says it's in talks with other potential partners. Release

> Gentium plans to submit an amendment to the protocol for its ongoing Phase III trial of Defibrotide of the treatment of hepatic veno-occlusive disease with multi-organ failure. Release

> Bayer is withdrawing the anti-clotting drug at the FDA's request, the agency says, after preliminary data from a new study showed Trasylol increased the risk of death. Report

> Pfizer isn't letting Lipitor go gently into the good night of off-patent drugs. It's fighting to keep the cholesterol remedy's sales up until the bitter end. Report

> U.S. drug regulators aren't playing fair, says outgoing Wyeth CEO Bob Essner. New meds that should be allowed on the market--because they're safe and effective--are blocked if they're not demonstrably better than existing products. Report

And Finally… Scientists at the University of Liverpool have discovered that mice rely on a special set of proteins to recognize each other. Release